Pharmacology, drug efficacy, and the individual

Drug Metabolism Reviews

Volumn 36, Issue 3-4, 2004, Pages 845-852

  Hildebrandt, Alfred G ^a  

^a NONE   (Germany)

Author keywords

Clinical trials; Drug efficacy; Drug regulation; Drug tailoring; Neglected diseases

Indexed keywords

ANALYTIC METHOD; CLINICAL TRIAL; DATA ANALYSIS; DISEASE MARKER; DRUG EFFICACY; HEALTH CARE AVAILABILITY; HUMAN; INDIVIDUALITY; MATHEMATICAL ANALYSIS; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; METHODOLOGY; PHARMACOGENETICS; PHARMACOGENOMICS; PHARMACOLOGY; REVIEW; SAMPLE SIZE;

CLINICAL TRIALS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 7544229429     PISSN: 03602532     EISSN: None     Source Type: Journal    
DOI: 10.1081/DMR-200033500     Document Type: Review

References (20)

1. Buchheim, R. (1859). Lehrbuch der Arzneimittellehre. Leipzig: Voss, p. 19.
2. Echt, D. S., Liebson, P. R., Mitchell, L. B., Petres, R. W., Obias-Manno, D., Barker, A. H., Friedman, L., Green, H. L., Huther, M. L., Richardson, D. W. (1991). Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac arrhythmia Suppression Trial. N. Engl. J. Med. 324:781-788.
3. Editorial. (2003). Investing in children for a better future. The Lancet 362(9394):1427.
4. Guyatt, G., Sackett, D., Taylor, D. W., Chong, J., Roberts, R., Pugsley, S. (1986). Determining optimal therapy - randomised trials in individual patients. N. Engl. J. Med. 314:889-892.
5. Habermann, E. (1988). Therapeutics - progress and control. An epistemological approach. Theor. Surg. 2:204-208.
6. Habermann, E. (1995). Wie wissenschaftlich ist unsere Arzneitherapie? Med. Welt 46:1-7.
7. Jonas, H. (1984). Das Prinzip Verantwortung. Versuch einer Ethik für die technologische Zivilisation. Vol. 156Suhrkamp Frankfurt am Main, pp. 61-64.
8. Koch, K. (1997). Hypertonie alpha-rezeptorenblocker gestoppt. Deutsches Ärzteblatt 13:648.
9. Lemonick, M. D. (2001). Gene mapper. the bad boy of science has jump-started a biological revolution. Time Europe. Vol. 156. 26, December 25.
10. Martini, P. (1932). Methodenlehre der Klinischen Prüfung. Springer Verlag.
11. Medical Research Council Investigation. (1948). Streptomycin treatment of pulmonary tuberculosis. Br. Med. J. 2:769.
12. Nash, J. M. (2000). Battle pending. Time. Vol. 155. p. 15. April 17.
13. National Institute of Health (NIH). (2002). NHLBI study finds traditional diuretics better than newer medicines for treating hypertension. http://www.nhlbi.nih.gov. December 17.
14. Roots, I., Gerloff, T., Meisel, C., Kirchheiner, J., Goldammer, M., Kaiser, R., Laschinski, G., Brockmöller, J., Cascorbi, I., Kleeberg, U., Hildebrandt, A. G. (2004). Pharmacogenetics-Based New Therapeutic Concepts. T & F Informa plc.
15. Schmiedeberg, O. (1909). Grundriss der Pharmakologie. Leipzig: F. C. W. Vogel, p. 12.
16. Stille, G. (1994). Der weg der arznei. Von der Materia Medica zur pharmakologie. Karlsruhe: G. Braun.
17. Temple, R. (1993). Trends in pharmaceutical developments. Drug Inf. J. 27:355-366.
18. Trouiller, P., Olliaro, P., Torreele, E., Orbinski, J., Laing, R., Ford, N. (2002). Drug development for neglected diseases: a deficient market and a public health policy failure. The Lancet 359:2188-2194.
19. Virchow, R. (1847). Über die Standpunkte in der wissenschaftlichen Medizin. Virchows Arch. 1:3-19.
20. World Health Organization. (2002). WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy 2000-2003. Geneva. WHO/HTP/ EDM2000. Http://www.who.int/medicines/strategy.pdf (accessed March 2, 2002).